Horizon Pharma begins phase 3 trial of Actimmune to treat Friedreich's Ataxia

Horizon Pharma begins phase 3 trial of Actimmune to treat Friedreich's Ataxia. Pharmabiz.com; Dublin, Ireland
Monday, June 08, 2015

Horizon Pharma plc, a biopharmaceutical company, has initiated the phase 3 Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich's Ataxia study (STEADFAST) of Actimmune (interferon gamma-1b) for the treatment of people with Friedreich's Ataxia (FA), a degenerative neuro-muscular disorder.